


## Single- and Multiple-Dose Clinical Trials (**ASCENT-1** and **ASCENT-2**) for Dose Finding of PRX012 in Participants With Biologically Confirmed Alzheimer's Disease

### ascent-1

#### Single-Dose Clinical Trial

**Treatment:** Single SC injection of PRX012 or placebo

**Participants With Early AD:** Amyloid PET positive, MMSE  $\geq 18$



**1 Primary Objective**  
To evaluate the safety and tolerability of PRX012 administered as a single dose

**2 Secondary Objective**  
To characterize the PK profile of PRX012 after SC administration as a single dose


**Study Duration**  
~3 months

### ascent-2

#### Multiple-Dose Clinical Trial

**Treatment:** Multiple SC injections of PRX012 or placebo

**Participants With Early AD:** Aged 55-85 years, amyloid PET eligible, MMSE  $\geq 18$



**1 Primary Objective**  
To evaluate the safety, tolerability, and immunogenicity of PRX012 after multiple SC doses

**2 Secondary Objective**  
To characterize the PK profile and PD effects on brain amyloid plaque deposition of PRX012 after multiple SC doses

**Study Duration**  
~6 months

### ascent-3

#### Open-Label Extension Trial

Participants who complete ASCENT-1 or ASCENT-2 may be eligible to enter into the open-label extension study, **ASCENT-3**

\*Group B increases representation of participants who are homozygous for *APOE4* to ~2x that of the general AD population.

PRX012 is an investigational drug and not approved by any regulatory authority.

AD, Alzheimer's disease; APOE4, apolipoprotein E4; MMSE, Mini-Mental State Examination; PD, pharmacodynamic; PET, positron emission tomography; PK, pharmacokinetic; SC, subcutaneous.

Swanson C, et al. Poster presentation at AAIC 2024; July 28-August 1, 2024; Philadelphia, PA, USA. Data as of August 1, 2024.

©2024 Prothena